Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BriaCell Therapeutics ( (TSE:BCT) ) has shared an announcement.
BriaCell Therapeutics will present four scientific posters at the 2026 American Association for Cancer Research Annual Meeting, showcasing clinical data from its pivotal Phase 3 trial of Bria-IMT combined with an immune checkpoint inhibitor and additional Phase 2 analyses. The company will also unveil preclinical findings for its next-generation Bria-OTS+ platform, which integrates innate and adaptive immunity for broad, durable anti-tumor responses across several cancers, underscoring its ambition to strengthen its position in cancer immunotherapy and highlight potential quality-of-life benefits for heavily pretreated metastatic breast cancer patients.
Data from the Phase 3 Bria-IMT study indicate heavily pretreated metastatic breast cancer patients maintained overall health status and key functional measures with a favorable safety profile, suggesting preservation of quality of life in a population with limited options. Preclinical results for Bria-OTS+ show activation of CD4+/CD8+ T cells, NK, NKT and B cells, along with increased cytokine release and sustained immune competence, which may enhance BriaCell’s competitive edge in the emerging field of personalized off-the-shelf immunotherapies.
The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on BCT Stock
According to Spark, TipRanks’ AI Analyst, BCT is a Neutral.
The score is driven primarily by weak financial performance: no revenue, widening losses, and substantial cash burn that increases funding risk. Technicals add modest pressure given the stock remains below key longer-term moving averages with negative MACD, while valuation offers limited support due to negative earnings and no indicated dividend.
To see Spark’s full report on BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel cancer immunotherapies. Its pipeline includes Bria-IMT, an immunotherapy for metastatic breast cancer, and Bria-OTS+, a next-generation personalized off-the-shelf whole-cell immunotherapy platform targeting multiple solid tumors such as breast, prostate, lung cancer and melanoma.
Average Trading Volume: 29,622
Technical Sentiment Signal: Sell
Current Market Cap: C$45.1M
See more insights into BCT stock on TipRanks’ Stock Analysis page.